On 31 August 2026, the first two participants received a dose of PVX-001, a broadly-protective COVID-19 vaccine candidate designed to protect against future SARS-CoV-2 variants, in a first-in-human Phase I clinical trial in Melbourne, Australia (ACT RN12626000891325). The trial will enroll 36 healthy adult volunteers to assess safety, tolerability, and immune response breadth. As of 6 October 2026, 14 participants have been enrolled and dosed with no serious adverse events reported.
PVX-001 was built using Pop Vax's computational protein design pipeline, mRNA-encoded VLP display architecture, fridge-stable lipid nanoparticle delivery via novel ionizable lipid PVXL-150, and in-house manufacturing at the RNA Foundry in Hyderabad. After Phase I concludes, the vaccine will be made open-source.
This milestone advances Pop Vax's Million Lives Mission to save 1 million lives annually through novel vaccines and therapeutics. The mRNA-LNP platform data will accelerate preclinical programs—including single-dose rabies, multivalent HCV, TB, and Strep A vaccines—into clinical trials within 2 years.
The founder reflects on a 5-year journey from reading about AlphaFold 2 to launching the trial, crediting early support from the Gates Foundation, Vitalik Buterin, and Balvi. Despite initial skepticism, the vaccine's first human injection marked a pivotal moment in pandemic preparedness.
Source: Hacker News · Summarized by HeadlinesBriefing